Keenova Therapeutics Plc Quick Ratio (MNK) starting from the first quarter 2026 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Keenova Therapeutics Plc  (MNK)

Keenova Therapeutics Plc's Quick Ratio

MNK's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Keenova Therapeutics Plc's Cash & cash equivalent grew by 1.49 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Keenova Therapeutics Plc's Quick Ratio to 1.29 a new company high.

Within Major Pharmaceutical Preparations industry 311 other companies have achieved higher Quick Ratio than Keenova Therapeutics Plc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 1402, from total ranking in the fourth quarter 2025 at 1593.

Explain Quick Ratio?
How much Cash & cash equivalents MNK´s has?
What are MNK´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

MNK Quick Ratio (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 26 2025)
Q3		 (Mar 28 2025)
Q1		 (Sep 27 2024)
Q3
Y / Y Current Liabilities Change 15.28 % 44.96 % 144.6 % -14.37 % -30.7 %
Y / Y Cash & cash equivalent Change 100.95 % 179.22 % 313.21 % 114.41 % 5.31 %
Quick Ratio MRQ 1.29 1.16 0.98 0.76 0.74
MNK's Total Ranking # 1402 # 1593 # 1250 # 1516 #
Seq. Current Liabilities Change -8.64 % -34.77 % 134.02 % -17.34 % 14.88 %
Seq. Cash & cash equivalent Change 1.49 % -22.44 % 200.95 % -15.18 % 41.02 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 312
Healthcare Sector # 546
Overall Market # 1402


Quick Ratio Statistics
High Average Low
1.29 0.69 0.15
(Mar 31 2026)   (Jun 30 2023)




Financial Statements
Keenova Therapeutics Plc's Current Liabilities $ 638 Millions Visit MNK's Balance sheet
Keenova Therapeutics Plc's Cash & cash equivalent $ 825 Millions Visit MNK's Balance sheet
Source of MNK's Sales Visit MNK's Sales by Geography


Cumulative Keenova Therapeutics Plc's Quick Ratio

MNK's Quick Ratio for the trailling 12 Months

MNK Quick Ratio

 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 26 2025)
12 Months		 (Mar 28 2025)
12 Months		 (Sep 27 2024)
12 Months
Y / Y Current Liabilities TTM Growth 42.71 % 23.42 % -48.98 % -63.44 % -63.6 %
Y / Y Cash & cash equivalent TTM Growth 171.46 % 138.8 % 63.07 % -13.84 % -36.5 %
Quick Ratio TTM 1.06 0.94 0.82 0.67 0.56
Total Ranking TTM # 2937 # 3080 # 2504 # 3221 #
Seq. Current Liabilities TTM Growth 3.04 % 8.45 % 32.79 % -3.82 % -10.89 %
Seq. Cash & cash equivalent TTM Growth 15.82 % 24.87 % 60.94 % 16.62 % 1.89 %

Quick ratio ranking by company, industry and sector >> Back to MNK Financial Strength Comparisons >> Go to Compare MNK Quick Ratio to its Competitors

On the trailing twelve months basis MNK Cash & cash equivalent more than doubled by 100.95 % in Q1 2026 year on year, faster than Current Liabilities, this led to increase in in Keenova Therapeutics Plc's Quick Ratio to 1.06, above MNK average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 392 other companies have achieved higher Quick Ratio than Keenova Therapeutics Plc. While Quick Ratio overall ranking has improved so far to 2937, from total ranking during the twelve months ending fourth quarter 2025 at 3080.

Explain Quick Ratio?
How much Cash & cash equivalents MNK´s has?
What are MNK´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 393
Healthcare Sector # 807
Within the Market # 2937


trailing twelve months Quick Ratio Statistics
High Average Low
1.09 0.59 0.28
(Mar 31 2026)   (Mar 29 2024)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Vistagen Therapeutics Inc   3.55 $ 45.403  Millions$ 12.795  Millions
Hepion Pharmaceuticals Inc   3.54 $ 2.603  Millions$ 0.736  Millions
Enanta Pharmaceuticals Inc  3.53 $ 163.774  Millions$ 46.442  Millions
Rani Therapeutics Holdings Inc   3.50 $ 43.403  Millions$ 12.395  Millions
Aquestive Therapeutics Inc   3.49 $ 110.734  Millions$ 31.753  Millions
Calcimedica Inc   3.48 $ 8.164  Millions$ 2.347  Millions
Inhibitor Therapeutics Inc   3.38 $ 1.291  Millions$ 0.382  Millions
Rhythm Pharmaceuticals Inc   3.32 $ 340.625  Millions$ 102.522  Millions
Tao Synergies Inc   3.30 $ 3.646  Millions$ 1.104  Millions
Arbutus Biopharma Corp  3.14 $ 17.003  Millions$ 5.409  Millions
Bolt Biotherapeutics Inc   3.12 $ 22.892  Millions$ 7.343  Millions
Kyntra Bio Inc   3.10 $ 87.237  Millions$ 28.114  Millions
Compass Pathways Plc  3.07 $ 466.389  Millions$ 151.904  Millions
Aptevo Therapeutics Inc   3.05 $ 14.525  Millions$ 4.760  Millions
Polaryx Therapeutics Inc   3.04 $ 3.080  Millions$ 1.014  Millions
Nanoviricides inc   3.02 $ 3.213  Millions$ 1.065  Millions
Kiniksa Pharmaceuticals International Plc  2.99 $ 468.093  Millions$ 156.611  Millions
Harmony Biosciences Holdings inc   2.95 $ 640.918  Millions$ 217.340  Millions
Foghorn Therapeutics Inc   2.85 $ 183.631  Millions$ 64.404  Millions
Hoth Therapeutics Inc   2.83 $ 4.047  Millions$ 1.433  Millions
Biomarin Pharmaceutical Inc  2.80 $ 2,222.435  Millions$ 793.152  Millions
Acadia Pharmaceuticals Inc   2.79 $ 851.458  Millions$ 305.524  Millions
Rafael Holdings Inc  2.79 $ 30.497  Millions$ 10.950  Millions
Oramed Pharmaceuticals Inc  2.77 $ 29.264  Millions$ 10.563  Millions
Tg Therapeutics Inc   2.75 $ 514.430  Millions$ 187.108  Millions
Verastem Inc   2.72 $ 181.678  Millions$ 66.845  Millions
Annovis Bio Inc   2.70 $ 14.219  Millions$ 5.276  Millions
Ionis Pharmaceuticals Inc   2.68 $ 1,919.113  Millions$ 716.591  Millions
Precigen Inc   2.67 $ 56.246  Millions$ 21.104  Millions
Ernexa Therapeutics Inc   2.65 $ 9.177  Millions$ 3.457  Millions

Date modified: 2026-09-26T06:54:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.